MoonLake Immunotherapeutics
moonlaketx.comWhat Do They Do?
Develops an investigational medicine for patients with inflammatory skin and joint diseases, including hidradenitis suppurativa and psoriatic arthritis.
10-K for FY2025, filed Feb 25, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$61.8MView ↗
- ▲ +12% (Loss)
- vs −$55.2M in Q2 FY2025
Broader target diseases
The earlier report identified HS and PsA as initial targets; the latest also names axSpA and PPP as target diseases.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Feb 25, 2026We are developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A…View ↗
We currently develop SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A…View ↗
Preparing for commercialization
The earlier report focused on clinical trials and scaling manufacturing for potential commercial needs; the latest adds plans for U.S. sales, marketing and distribution capabilities.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Feb 25, 2026Strengthening the differentiation elements for future SLK patients — In parallel with our clinical trials, we conduct non-clinical research…View ↗
Loading...
